SCHEMBL319645

SCHEMBL319645

CC(=O)OC1=CC=COC1

nearest known ligand 0.38

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.31
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10595557 0.73
SCHEMBL3192528 0.71
SCHEMBL11414414 0.69
SCHEMBL29889544 0.68 LMNA (0.31) LMNA
SCHEMBL20094563 0.68 LMNA (0.39) LMNAKDM4EALDH1A1GAATSHR
SCHEMBL22007000 0.68 LMNA (0.39) LMNAKDM4EALDH1A1GAATSHR
SCHEMBL2758566 0.67 GLA (0.33) LMNAKDM4EALDH1A1GAATSHR
SCHEMBL31376461 0.65 LMNA (0.35) LMNAKDM4EALDH1A1GAA
SCHEMBL31648648 0.65
SCHEMBL30180803 0.64 LMNA (0.31) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0076075-A1 Pharmaceutically active benzopyran compounds BEECHAM GROUP PLC (GB) 1983-04-06 EP claimed
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2025-08-14 US disclosed
US-12319672-B2 Alpha-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-03 US disclosed
WO-2025024707-A1 INHIBITORS OF CDK2/4/6 KINASE KINNATE BIOPHARMA INC. (US) 2025-01-30 WO disclosed
EP-4097138-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS Avila Therapeutics, Inc. (US) 2022-12-07 EP disclosed
US-20220281855-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2022-09-08 US disclosed
CN-103080106-A Cyclic ether compounds useful as kinase inhibitors NOVARTIS AG 2013-05-01 CN disclosed
CN-100390153-C Intermediate for producing novel pyrazine derivatives TOYAMA CHEMICAL CO LTD (JP) 2008-05-28 CN disclosed
CN-1781911-A Intermediate for producing novel pyrazine derivatives TOYAMA CHEMICAL CO LTD (JP) 2006-06-07 CN disclosed
CN-1239511-C Novel pyrazine derivative or salt thereof, and pharmaceutical composition containing the same TOYAMA CHEMICAL CO LTD (JP) 2006-02-01 CN disclosed
CN-1418220-A Novel pyrazine derivative or salt thereof, pharmaceutical composition containing same, and intermediate for producing both TOYAMA CHEMICAL CO LTD (JP) 2003-05-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257056-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 LMNA 964/4885KDM4E 4329/4885ALDH1A1 251/4885
US-20220281855-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 LMNA 1998/4885KDM4E 4515/4885ALDH1A1 134/4885
US-12319672-B2 Alpha-D-galactopyranoside derivatives LGALS1, LGALS3, LGALS2 LMNA 1998/4885KDM4E 4515/4885ALDH1A1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.